Ionis to get up to $300 million from licensing deal with AstraZeneca
(Reuters) - Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Fatty Liver Disease (FLD) | Health | Liver | Liver Disease | Urology & Nephrology